CD44s and CD44v8-10 isoforms confer acquired resistance to osimertinib by activating the ErbB3/STAT3 signaling pathway.

Liu, Yi-Nan; Tsai, Meng-Feng; Wu, Shang-Gin; Chang, Tzu-Hua; Shih, Jin-Yuan

Liu, Yi-Nan; Tsai, Meng-Feng; Wu, Shang-Gin; Chang, Tzu-Hua; Shih, Jin-Yuan.

Afiliación

Liu YN; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Tsai MF; Department of Biomedical Sciences, Da-Yeh University, Changhua, Taiwan.
Wu SG; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Cancer Center, Taipei, Taiwan.
Chang TH; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan.
Shih JY; Department of Internal Medicine, National Taiwan University Hospital, Taipei, Taiwan; Graduate Institute of Clinical Medicine, College of Medicine, National Taiwan University, Taipei, Taiwan. Electronic address: jyshih@ntu.edu.tw.

Life Sci ; 336: 122345, 2024 Jan 01.

Article en En | MEDLINE | ID: mdl-38092140

Asunto(s)

Neoplasias Pulmonares; Humanos; Isoformas de Proteínas/genética; Neoplasias Pulmonares/tratamiento farmacológico; Neoplasias Pulmonares/genética; Neoplasias Pulmonares/patología; Compuestos de Anilina/farmacología; Receptores ErbB/genética; Receptores ErbB/metabolismo; Transducción de Señal; Resistencia a Antineoplásicos/genética; Línea Celular Tumoral; Receptores de Hialuranos/genética; Receptores de Hialuranos/metabolismo; Factor de Transcripción STAT3/genética; Factor de Transcripción STAT3/metabolismo

Palabras clave

Acquired resistance; CD44 isoform; Lung cancer; Osimertinib

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Base de datos: MEDLINE Asunto principal: Neoplasias Pulmonares Límite: Humans Idioma: En Revista: Life Sci Año: 2024 Tipo del documento: Article País de afiliación: Taiwán

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google